DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the J B CHEMICALS AND PHARMA (JBCHEPHARM) share price today?

J B CHEMICALS AND PHARMA (JBCHEPHARM) is trading at ₹2,408.9 on the NSE, down 3.87% on the day. Source: DocStoX.

What is the PE ratio of J B CHEMICALS AND PHARMA?

J B CHEMICALS AND PHARMA has a price-to-earnings (PE) ratio of 54.5 in the Healthcare sector.

What is the market capitalisation of J B CHEMICALS AND PHARMA?

J B CHEMICALS AND PHARMA has a market capitalisation of approximately ₹38,676 crore.

J B CHEMICALS AND PHARMA

JBCHEPHARM·NSE·Healthcare

₹2,408.90▼ -97.10 (-3.87%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

NIFTY 500NIFTY SMALLCAP 250NIFTY PHARMA

Day₹2380.00

₹2525.50

52W₹1639

₹252687%

Open

₹2506.00

High

₹2525.50

Low

₹2380.00

Prev Close

₹2506.00

Volume

47.79L

VWAP

₹2418.56

Snapshot

Key fundamentals

Market Cap

₹38,676 Cr

P/E Ratio

54.51Expensive

P/B Ratio

8.96

EPS

₹44.19

Book Value

₹259.00

ROE

18.90%Strong

ROCE

25.00%Efficient

Dividend Yield

0.90%

Debt / Equity

0.00Low

Face Value

₹1.00

52W High

₹2525.50

52W Low

₹1638.50

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹377

▼ 84.3%downside

Trading at ₹2,409 — 84% above our estimate

BearFair valueBull

₹321₹377₹507

/100

Business quality — Solid

Growth 59Profitability 77Efficiency 43Valuation 50

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 1/9)

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 25%)
Profit growing 20% a year

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

19% ROE fading to 12% over ~10 yrs, on ₹259 book

₹341

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹507

Analyst target

No analyst coverage

—

Blended fair value₹377

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 25%)
Profit growing 20% a year

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

54.5Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

18.9%Strong

Above 15% is considered healthy for Indian equities

ROCE

25.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹38,676 Cr

P/B

8.96

EPS

₹44.19

Div Yield

0.90%

What changed

Recent changes

Foreign investors+1.8% stake last quarter
Domestic institutions-1.3% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 54.5×

Growth

Steady

+10% rev CAGR

Profitability

Excellent

18.9% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %66.8%

Turnover₹115588.43L Cr

Trades1,57,981

VWAP₹2418.56

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+9.6%

+15.2%

10Y

+13.1%

Profit

+20.0%

+9.6%

10Y

+15.8%

EPS

+18.6%

+8.8%

10Y

+16.5%

Profile

Pros

Company has reduced debt.
Company is almost debt free.
Company has been maintaining a healthy dividend payout of 40.3%
Promoter holding has increased by 1.25% over last quarter.

Watch-outs

Cons

Stock is trading at 9.40 times its book value
Promoter holding has decreased over last 3 years: -5.13%
Working capital days have increased from 86.6 days to 126 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 1.77 pts; domestic institutions reduced 1.33 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

49%

Promoter

Promoters

48.8%+0.02

Public

13.5%+1.45

FII / FPI

16.3%+1.77

DII

21.4%-1.33

Total shareholders

74,043+5,077 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter48.80%

FII16.33%

DII21.38%

Public13.48%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions